- Trials with a EudraCT protocol (278)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
278 result(s) found for: Serological Test.
Displaying page 1 of 14.
EudraCT Number: 2020-002641-42 | Sponsor Protocol Number: C4591001 | Start Date*: 2020-09-04 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COV... | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006539-29 | Sponsor Protocol Number: 0 | Start Date*: 2008-03-14 |
Sponsor Name:Dept of Rheumatology, Lund University Hospital, Lund, Sweden | ||
Full Title: Effects of different anti-rheumatic treatments of arthritis on antibody response following pneumococcal vaccination using Prevenar | ||
Medical condition: Patients with rheumatic diseases (rheumatoid arthritis and spondyloarthripaties) who are going to be vaccinated with Prevenar vaccine in order to study the serological responses to two pneumococc... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001300-37 | Sponsor Protocol Number: S201.3.125 | Start Date*: 2006-07-11 |
Sponsor Name:Solvay Pharmaceuticals B.V. | ||
Full Title: Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: adult subjects... | ||
Medical condition: Prophylaxis of influenza, especially in those who run an increased risk of associated complications. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003041-35 | Sponsor Protocol Number: TJB2224 | Start Date*: 2022-10-20 |
Sponsor Name:CHU de Liège | ||
Full Title: Impact of the immune system on response to inactivated influenza vaccine (IIV) in allogeneic stem cell recipients | ||
Medical condition: Allogeneic hematopoietic stem cell recipients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003692-39 | Sponsor Protocol Number: PCV-ESA 2006 | Start Date*: 2006-03-08 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA | |||||||||||||
Full Title: Evaluation of immunogenicity of 7-valent Pneumococcal Conjugate Vaccine (Prevenar) and Hexavalent DtPa-HBV-IPV-Hib (InfaNrix Hexa), co-administered at the same time, versus Hexavalent vaccine, use... | |||||||||||||
Medical condition: Healthy children | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000341-11 | Sponsor Protocol Number: S206.3.010 | Start Date*: 2005-06-06 |
Sponsor Name:Solvay Pharmaceuticqals B.V. | ||
Full Title: Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac® for the season 2005/2006. An open, baseline controlled study in two groups of healthy subjects: adult subject... | ||
Medical condition: Prophylaxis of influenza in adults and the elderly, especially in those who run an increased risk of associated complications. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003791-38 | Sponsor Protocol Number: S206.3.011 | Start Date*: 2008-08-23 |
Sponsor Name:Solvay Pharmaceuticals B.V. | ||
Full Title: Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac® for the season 2005/2006. An open, baseline controlled study in two groups of healthy subjects: adult subject... | ||
Medical condition: Prophylaxis of influenza in adults and the elderly, especially in those who run an increased risk of associated complications. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001301-28 | Sponsor Protocol Number: S206.3.012 | Start Date*: 2006-05-19 |
Sponsor Name:Solvay Pharmaceuticals B.V. | ||
Full Title: Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac® for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: adult subject... | ||
Medical condition: Prophylaxis of influenza in adults and the elderly, especially in those who run an increased risk of associated complications. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004518-40 | Sponsor Protocol Number: PCV13-HIV2011 | Start Date*: 2011-10-25 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SENESE | |||||||||||||
Full Title: Serological response to antipneumococcal vaccination and consequent impact on Streptococcus pneumoniae nasal carriage in HIV positive adults: a prospective study using 13-valent conjugate vaccine | |||||||||||||
Medical condition: HIV positive adults with out previous PPV23 or PCV7 vaccination | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003596-17 | Sponsor Protocol Number: CMAS825D12201 | Start Date*: 2021-03-09 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A three-period multicenter study, with a randomized withdrawal, double-blinded, placebo-controlled design in Period 2 to evaluate the clinical efficacy, safety and tolerability of MAS825 in NLRC4-G... | |||||||||||||
Medical condition: NLRC4-GOF, AIFEC (autoinflammation with infantile enterocolitis) | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) CZ (Ongoing) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001978-37 | Sponsor Protocol Number: CombiVacS | Start Date*: 2021-04-19 |
Sponsor Name:Instituto de Salud Carlos III. ISCIII | ||
Full Title: A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the safety and immunogenicity of one dose of COMIRNATY in subjects that had received one dose of VAXZEVRIA. | ||
Medical condition: Covid-19 Vaccination | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017052-27 | Sponsor Protocol Number: 200910H1N1MHH | Start Date*: 2010-02-09 | |||||||||||
Sponsor Name:Medizinische Hochschule Hannover | |||||||||||||
Full Title: A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transp... | |||||||||||||
Medical condition: Vaccination for H1N1sw of immunocompromised adults who have undergone solid organ or bone marrow transplantation and of healthy adults | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001612-62 | Sponsor Protocol Number: ITMC0211 | Start Date*: 2011-09-06 |
Sponsor Name:Institute of Tropical Medicine Antwerp | ||
Full Title: Simplifying the Rabies Pre-exposure Vaccination | ||
Medical condition: Rabies is a viral infection that affects the central nervous system. It causes encephalitis which is almost invariably fatal. Preventive vaccination alone implies no complete protection, but simpli... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004863-69 | Sponsor Protocol Number: 108494, 108516, 108518, 108520 | Start Date*: 2006-12-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, single-blind, randomized, controlled, multicentre vaccination study to evaluate the safety and immune response of the GSK Biologicals Zoster vaccine, gE/AS01B, and to compare 3 doses of... | ||
Medical condition: Primary immunization of healthy elderly subjects (60 to 69 and more than or equal to 70 years) against zoster | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) SE (Completed) CZ (Completed) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001512-28 | Sponsor Protocol Number: COVIM | Start Date*: 2021-05-11 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: Immunogenicity of COVID-19 vaccines in medical staff and special risk populations | |||||||||||||
Medical condition: SARS-CoV-2 immunogenicity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002984-23 | Sponsor Protocol Number: 33-391ex20/21 | Start Date*: 2021-08-01 |
Sponsor Name:Medical University of Graz | ||
Full Title: Retrospective quantification of anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in patients treated with peritoneal dialysis | ||
Medical condition: Chronic peritoneal dialysis patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014315-12 | Sponsor Protocol Number: LIS143 | Start Date*: 2010-04-08 |
Sponsor Name:CIB/RIVM | ||
Full Title: Immunogenicity of alternate and reduced immunization schedules using the regular thirteen-valent polysaccharide conjugate vaccine against infection with Streptococcus pneumoniae | ||
Medical condition: Immunogenicity of alternate and reduced immunization schedules using the regular thirteen-valent polysaccharide conjugate vaccine against infection with Streptococcus pneumoniae | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002584-63 | Sponsor Protocol Number: VAC31518COV2001 | Start Date*: 2020-09-02 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults ... | |||||||||||||
Medical condition: Healthy Volunteers (Prevention of COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) ES (Restarted) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002258-22 | Sponsor Protocol Number: 209141 | Start Date*: 2019-11-13 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: Phase II randomized, observer-blind, placebo-controlled, multi-country study in healthy non-pregnant women 18-45 years of age to evaluate the safety, reactogenicity and immunogenicity of a 1st intr... | ||
Medical condition: Healthy Volunteers (prevention of lower respiratory tract illness) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000875-40 | Sponsor Protocol Number: S201.3.126 | Start Date*: 2007-05-25 | |||||||||||
Sponsor Name:Solvay Pharmaceuticals B.V. | |||||||||||||
Full Title: Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2007/2008. An open, baseline-controlled multi-centre study in two groups of healthy subjects: ... | |||||||||||||
Medical condition: Prophylaxis of influenza. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.